NCT02916979View on ClinicalTrials.gov

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 6, 2016

Primary Completion Date

June 7, 2019

Study Completion Date

February 11, 2022

Conditions
Leukemia, LymphoidLeukemia, MyeloidMyelodysplastic SyndromesMyelofibrosisLymphoma, MalignantMultiple MyelomaWaldenstrom Macroglobulinemia
Interventions
DRUG

Fludarabine

Fludarabine: 30 mg/m2 daily for 5 days

DRUG

Busulfan

Busulfan: 100 mg/m2 daily for 4 days

BIOLOGICAL

Rabbit ATG

"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"

DRUG

Methotrexate

"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | Biotech Hunter | Biotech Hunter